Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research
Keywords: 
Genomics
Proteomics
Heart failure
Issue Date: 
2009
Publisher: 
Elsevier
Publisher Version: 
ISSN: 
0300-8932
Citation: 
Gonzalez A, Lopez B, Beaumont J, Ravassa S, Arias T, Hermida N, et al. Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. Rev Esp Cardiol 2009 Mar;62(3):305-313.
Abstract
Heart failure is a complex syndrome and is one of the main causes of morbidity and mortality in developed countries. Despite considerable research effort in recent years, heart failure prevention and treatment strategies still suffer significant limitations. New theoretical and technical approaches are, therefore, required. It is in this context that the «omic» sciences have a role to play in heart failure. The incorporation of «omic» methodologies into the study of human disease has substantially changed biological approaches to disease and has given an enormous impetus to the search for new disease mechanisms, as well as for novel biomarkers and therapeutic targets. The application of genomics, proteomics and metabonomics to heart failure research could increase our understanding of the origin and development of the different processes contributing to this syndrome, thereby enabling the establishment of specific diagnostic profiles and therapeutic templates that could help improve the poor prognosis associated with heart failure. This brief review contains a short description of the fundamental principles of the «omic» sciences and an evaluation of how these new techniques are currently contributing to research into human heart failure. The focus is mainly on the analysis of gene expression microarrays in the field of genomics and on studies using two-dimensional electrophoresis with mass spectrometry in the area of proteomics.

Files in This Item:
There are no files associated with this item.


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.